Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01280
|
|||||
| Drug Name |
Enoxacin
|
|||||
| Synonyms |
1,8-Naphthyridine-3-carboxylic acid, 6-fluoro-1,4-dihydro-4-oxo-7-piperazinyl; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid; AT 2266; AT-2266; AT2266; Almitil; Almitil (TN); Bactidan; Bactidan (TN); Bactidron (TN); CI919; CL23362; Comprecin; Comprecin (TN); E0762; Enoksetin (TN); Enoram; Enoxacin (USAN/INN); Enoxacin Sesquihydrate; Enoxacin [USAN:BAN:INN:JAN]; Enoxacine; Enoxacine [French]; Enoxacino; Enoxacino [Spanish]; Enoxacinum; Enoxacinum [Latin]; Enoxen (TN); Enoxin; Enoxin (TN); Enoxor; Enoxor (TN); Enroxil (TN); Faulding Brand of Enoxacin; Flumark; Flumark (TN); Gyramid (TN); PD 107779; PD-107779; PD107779; Penetrex; Penetrex (TN); Pierre Fabre Brand of Enoxacin Sesquihydrate; Rhone Poulenc Rorer Brand of Enoxacin Sesquihydrate; Rhone-Poulenc Rorer Brand of Enoxacin Sesquihydrate; Sesquihydrate, Enoxacin; Vinone (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Urinary tract infections [ICD11: GC08] | Approved | [1] | |||
| Gonorrhea [ICD11: 1A70-1A7Z] | Approved | [1] | ||||
| Therapeutic Class |
Antiinfective Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C15H17FN4O3
|
|||||
| Canonical SMILES |
CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O
|
|||||
| InChI |
InChI=1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23)
|
|||||
| InChIKey |
IDYZIJYBMGIQMJ-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 74011-58-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 320.32 | Topological Polar Surface Area | 85.8 | ||
| Heavy Atom Count | 23 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
-0.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
9193
, 494643
, 598045
, 855964
, 7656850
, 7847376
, 7979166
, 8149934
, 8152051
, 10321663
, 11112842
, 11335595
, 11360834
, 11364433
, 11366995
, 11369557
, 11372679
, 11373790
, 11377719
, 11414007
, 11461806
, 11466381
, 11467501
, 11485538
, 11486102
, 11489547
, 11491385
, 11491981
, 11495353
, 12012631
, 14899277
, 24894528
, 26612426
, 26680210
, 26747059
, 26747060
, 29222370
, 46507505
, 47216718
, 47365122
, 47365123
, 47440190
, 47736413
, 47885347
, 48110393
, 48110394
, 48184940
, 48334424
, 48415943
, 49698449
|
|||||
| ChEBI ID |
CHEBI:157175
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MATE1 | Transporter Info | Multidrug and toxin extrusion protein 1 | Substrate | [2] | |
| OATP1A2 | Transporter Info | Organic anion transporting polypeptide 1A2 | Substrate | [3] | ||
| References | ||||||
| 1 | Enoxacin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Functional characterization of multidrug and toxin extrusion protein 1 as a facilitative transporter for fluoroquinolones. J Pharmacol Exp Ther. 2009 Feb;328(2):628-34. | |||||
| 3 | Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.